Preoperative treatment and surgery in gastric cancer: friends or foes?

Risultato della ricerca: Contributo in rivistaArticolo in rivista

44 Citazioni (Scopus)

Abstract

Until 2006, most reports of preoperative (neoadjuvant) treatments for gastric carcinoma were inconclusive and produced confusing results due to inhomogeneous treatment regimens, selection of patients, and response assessment. Since publication of the results from the MAGIC trial, substantial scientific evidence has suggested the benefits of perioperative (preoperative and postoperative) chemotherapy to locally advanced gastric cancer. To date, this phase III trial, coupled with preliminary data from other published reports on neoadjuvant chemotherapy and radiotherapy, supports the theoretical advantages of preoperative treatment for gastric carcinoma, thus introducing the concept of delayed surgery. Neoadjuvant treatment of resectable, locally advanced tumours might improve patients' outcomes and postpone the need for curative resection, but it also exposes patients to the risk of tumour progression.
Lingua originaleEnglish
pagine (da-a)191-195
Numero di pagine5
RivistaLANCET ONCOLOGY
Volume10
DOI
Stato di pubblicazionePubblicato - 2009

Keywords

  • Antineoplastic Agents
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Digestive System Surgical Procedures
  • Humans
  • Neoadjuvant Therapy
  • Stomach Neoplasms

Fingerprint Entra nei temi di ricerca di 'Preoperative treatment and surgery in gastric cancer: friends or foes?'. Insieme formano una fingerprint unica.

Cita questo